Publicaciones en las que colabora con José María López-Picazo González (25)

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

2021

  1. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

2020

  1. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients

    Disease Markers, Vol. 2019

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2016

  1. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

2015

  1. Functional expression of CD137 (4-1BB) on T helper follicular cells

    OncoImmunology, Vol. 4, Núm. 12

2014

  1. Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging

  2. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

  3. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

  4. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Núm. 11, pp. 2058-2065

  5. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. The multimodal management of locally advanced N2 non-small cell lung cancer: Is there a role for surgical resection? A single institution's experience

    Clinical and Translational Oncology, Vol. 14, Núm. 11, pp. 835-841

2009

  1. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer

    World Journal of Gastroenterology, Vol. 15, Núm. 18, pp. 2290-2292

  2. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

  3. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin b12 and folic acid supplementation for advanced non-small cell lung cancer

    Onkologie, Vol. 32, Núm. 10, pp. 580-584

2007

  1. Carcinoma microcítico de pulmón

    Revista de medicina, Vol. 51, Núm. 2, pp. 7-13